Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.1500 (3.36%) ($5.8400 - $6.1900) on Mon. Dec. 2, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.69% (three month average) | RSI | 75 | Latest Price | $6.1500(3.36%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 2.1% a day on average for past five trading days. | Weekly Trend | ADMS advances 2.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(12%) UNG(9%) BWX(7%) SLV(5%) VIXM(4%) | Factors Impacting ADMS price | ADMS will decline at least -2.845% in a week (0% probabilities). URA(-22%) BLOK(-16%) XLE(-15%) XLK(-14%) ACES(-14%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.845% (StdDev 5.69%) | Hourly BBV | 0 () | Intraday Trend | 2% | | | |
|
5 Day Moving Average | $5.74(7.14%) | 10 Day Moving Average | $5.61(9.63%) | 20 Day Moving Average | $5.38(14.31%) | To recent high | -17.6% | To recent low | 20.1% | Market Cap | $174m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |